Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® compared to a powder inhaler in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®
Interventions
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients aged at least 18 years * Patients who are suffering from symptoms of a chronic obstructive lung disease (COLD) can be included in the PMS. To reduce influences caused by the use of a variety of different powder inhaler, only patients who are already regularly using Diskus® powder inhaler should be included, as the Diskus® as well as the Berodual® Respimat® are multiple dose devices * During the PMS the Diskus® therapy is to be continued
Exclusion criteria
* Patients who meet one or more of the general or specific contraindications mentioned in the Summary of Product Characteristics (SmPC) are excluded from the Postmarketing Surveillance (PMS)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events | up to 4 weeks |
| Number of patients who prematurely discontinued therapy with Berodual® Respimat® | up to 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of patient satisfaction with regard to handling of Berodual® Respimat® inhaler | up to 4 weeks | by means of a patient satisfaction and preference questionnaire (PASAPQ) |
| Assessment of patient satisfaction with regard to handling of Diskus® inhaler | Baseline | by means of patient satisfaction and preference questionnaire (PASAPQ) |
Outcome results
None listed